Predicting the impact of physiological and biochemical processes on oral drug bioavailability.

Recent advances in computational methods applied to the fields of drug delivery and biopharmaceutics will be reviewed with a focus on prediction of the impact of physiological and biochemical factors on simulation of gastrointestinal absorption and bioavailability. Our application of a gastrointestinal simulation for the prediction of oral drug absorption and bioavailability will be described. First, we collected literature data or we estimated biopharmaceutical properties by application of statistical methods to a set of 2D and 3D molecular descriptors. Second, we integrated the differential equations for an advanced compartmental absorption and transit (ACAT) model in order to determine the rate, extent, and approximate gastrointestinal location of drug liberation (for controlled release), dissolution, passive and carrier-mediated absorption, and saturable metabolism and efflux. We predict fraction absorbed, bioavailability, and C(p) vs. time profiles for common drugs and compare those estimates to literature data. We illustrate the simulated impact of physiological and biochemical processes on oral drug bioavailability.

[1]  D. Greenblatt,et al.  Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole , 1999, Clinical pharmacology and therapeutics.

[2]  Morton B. Brown,et al.  Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. , 1997, The Journal of clinical investigation.

[3]  R. Oertel,et al.  Intestinal secretion of intravenous talinolol is inhibited by luminal R‐verapamil , 1999, Clinical pharmacology and therapeutics.

[4]  A. Boobis,et al.  Human cytochromes P-450. , 1984, Xenobiotica; the fate of foreign compounds in biological systems.

[5]  W. Higuchi,et al.  Theoretical model studies of drug absorption and transport in the GI tract. 3. , 1972, Journal of pharmaceutical sciences.

[6]  P J Sinko,et al.  Development of predictive pharmacokinetic simulation models for drug discovery. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[7]  S. Krähenbühl,et al.  Interaction between grapefruit juice and midazolam in humans , 1995, Clinical pharmacology and therapeutics.

[8]  Y. Tam.  Individual Variation in First-Pass Metabolism , 1993, Clinical pharmacokinetics.

[9]  D. Back,et al.  Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. , 1999, British journal of clinical pharmacology.

[10]  K. Higaki,et al.  Prediction of the Plasma Concentration Profiles of Orally Administered Drugs in Rats on the Basis of Gastrointestinal Transit Kinetics and Absorbability , 1997, The Journal of pharmacy and pharmacology.

[11]  J. S. Wang,et al.  Midazolam alpha-hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole. , 1999, Pharmacology & toxicology.

[12]  J. Kolars,et al.  Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[13]  J. Leonard,et al.  Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir * , 1998, Clinical pharmacology and therapeutics.

[14]  U. Kunzendorf,et al.  Saturable First‐Pass Kinetics of Propranolol , 1989, Journal of clinical pharmacology.

[15]  R. T. Coutts,et al.  A computer simulation of the food effect: transient changes in hepatic blood flow and Michaelis-Menten parameters as mediators of hepatic first pass metabolism and bioavailability of propranolol. , 1990, Biopharmaceutics & drug disposition.

[16]  D. Dunbar,et al.  Characterization of human small intestinal cytochromes P-450. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[17]  G L Amidon,et al.  Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. , 1996, Advanced drug delivery reviews.

[18]  Y. Sugiyama,et al.  Prediction of in vivo nonlinear first-pass hepatic metabolism of YM796 from in vitro metabolic data. , 1998, The Journal of pharmacology and experimental therapeutics.

[19]  N. Holford,et al.  Dose-dependent elimination of propranolol and its major metabolites in humans. , 1983, Journal of pharmaceutical sciences.

[20]  T Lavé,et al.  Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques. , 1999, Journal of medicinal chemistry.

[21]  S. Krähenbühl,et al.  Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. , 1998, British journal of clinical pharmacology.

[22]  M. E. Fitzsimmons,et al.  Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[23]  R. Remmel,et al.  First-pass disposition of (-)-6-aminocarbovir in rats. I. Prodrug activation may be limited by access to enzyme. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[24]  H Lennernäs,et al.  Membrane transport of drugs in different regions of the intestinal tract of the rat. , 1998, Journal of pharmaceutical sciences.

[25]  J. Wagner.  Propranolol: Pooled Michaelis‐Menten parameters and the effect of input rate on bioavailability , 1985, Clinical pharmacology and therapeutics.

[26]  P. Gwilt,et al.  The influence of diffusional barriers on presystemic gut elimination. , 1988, Drug metabolism and disposition: the biological fate of chemicals.

[27]  B. Stoll,et al.  A theory of molecular absorption from the small intestine , 2000 .

[28]  P. Watkins,et al.  The barrier function of CYP3A4 and P-glycoprotein in the small bowel. , 1997, Advanced drug delivery reviews.

[29]  S. Su,et al.  Inhibition of the intestinal digoxin absorption and exsorption by quinidine. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[30]  R. Hänsel,et al.  Immunomodulating Properties of 5,20α(R)-Dihydroxy-6α,7α-epoxy-1-oxo-(5α)-witha-2,24-dienolide and Solasodine , 1982 .

[31]  J. Monasterio,et al.  Plasma concentrations and bioavailability of propranolol by oral, rectal, and intravenous administration in man. , 1986, Biopharmaceutics & drug disposition.

[32]  H K Kroemer,et al.  The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. , 1999, The Journal of clinical investigation.

[33]  J. Kanto,et al.  Midazolam: The First Water‐soluble Benzodiazepine; Pharmacology, Pharmacokinetics and Efficacy in Insomnia and Anesthesia , 1985, Pharmacotherapy.

[34]  W. H. Barr,et al.  Intestinal drug absorption and metabolism. I. Comparison of methods and models to study physiological factors of in vitro and in vivo intestinal absorption. , 1970, Journal of pharmaceutical sciences.

[35]  Lawrence X. Yu,et al.  Compartmental transit and dispersion model analysis of small intestinal transit flow in humans , 1996 .

[36]  R. Fontana,et al.  Molecular and physical mechanisms of first-pass extraction. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[37]  J. Silverman,et al.  Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. , 1998, The Journal of pharmacology and experimental therapeutics.

[38]  Y. Sugiyama,et al.  Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozymes. , 1997, The Journal of pharmacology and experimental therapeutics.

[39]  M. Gray,et al.  Models of hepatic drug elimination. , 1992, Drug metabolism reviews.

[40]  P Langguth,et al.  Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein. , 1999, Journal of pharmaceutical sciences.

[41]  R. Weaver,et al.  Prediction of interindividual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically based pharmacokinetic modeling. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[42]  L. Benet,et al.  Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy , 1995, Molecular carcinogenesis.

[43]  G L Amidon,et al.  A compartmental absorption and transit model for estimating oral drug absorption. , 1999, International journal of pharmaceutics.

[44]  R. Brauer.  Liver circulation and function. , 1963, Physiological reviews.

[45]  B. Hoener,et al.  Predicting the hepatic clearance of xenobiotics in humans from in vitro data , 1994, Biopharmaceutics & drug disposition.

[46]  D. Shen,et al.  First‐pass metabolism of midazolam by the human intestine , 1996, Clinical pharmacology and therapeutics.

[47]  W. Higuchi,et al.  Theoretical model studies of drug absorption and transport in the gastrointestinal tract.i. , 1970, Journal of pharmaceutical sciences.

[48]  J. Kolars,et al.  CYP3A gene expression in human gut epithelium. , 1994, Pharmacogenetics.

[49]  W. Jusko,et al.  Michaelis-Menten metabolite formation kinetics: equations relating area under the curve and metabolite recovery to the administered dose. , 1990, Journal of pharmaceutical sciences.

[50]  J B Houston,et al.  Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. , 1997, Drug metabolism reviews.

[51]  T. Walle,et al.  Food effects on propranolol systemic and oral clearance: Support for a blood flow hypothesis , 1986, Clinical pharmacology and therapy.

[52]  J. Aronson.  Clinical Pharmacokinetics of Digoxin 1980 , 1980, Clinical pharmacokinetics.

[53]  T. Lavé,et al.  Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration-time transformations. , 1995, Journal of pharmaceutical sciences.

[54]  G. Amidon,et al.  Physicochemical model for dose-dependent drug absorption. , 1984, Journal of pharmaceutical sciences.

[55]  B. Brodie,et al.  On the mechanism of intestinal absorption of drugs. , 1959, The Journal of pharmacology and experimental therapeutics.

[56]  L. Benet,et al.  Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers. , 1998, Biochemical pharmacology.

[57]  K. Arimori,et al.  The intestinal dialysis of intravenously administered phenytoin by oral activated charcoal in rats. , 1987, Journal of pharmacobio-dynamics.

[58]  Y. Sugiyama,et al.  Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[59]  T Lavé,et al.  Prediction of Hepatic Metabolic Clearance Based on Interspecies Allometric Scaling Techniques and In Vitro-In Vivo Correlations , 1999, Clinical pharmacokinetics.

[60]  P. Swaan,et al.  Mapping the binding site of the small intestinal peptide carrier (PepT1) using comparative molecular field analysis. , 1998, Receptors & channels.

[61]  G L Amidon,et al.  Saturable small intestinal drug absorption in humans: modeling and interpretation of cefatrizine data. , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[62]  M. H. Jacobs.  SOME ASPECTS OF CELL PERMEABILITY TO WEAK ELECTROLYTES , 1940 .

[63]  S. Pond,et al.  First-Pass Elimination Basic Concepts and Clinical Consequences , 1984, Clinical pharmacokinetics.

[64]  W. Higuchi,et al.  Quantitative interpretation of in vivo buccal absorption of n-alkanoic acids by the physical model approach. , 1971, Journal of pharmaceutical sciences.

[65]  D. Shen,et al.  Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.

[66]  J. Meier.  Pharmacokinetic comparison of pindolol with other beta-adrenoceptor-blocking agents. , 1982, American heart journal.

[67]  J. Lipsky,et al.  Drug-grapefruit juice interactions. , 2000, Mayo Clinic proceedings.

[68]  Thomas J. Raub,et al.  Passive diffusion of weak organic electrolytes across Caco-2 cell monolayers: uncoupling the contributions of hydrodynamic, transcellular, and paracellular barriers. , 1995, Journal of pharmaceutical sciences.

[69]  D. Greenblatt,et al.  Bioavailability of Drugs: The Digoxin Dilemma , 1976, Clinical pharmacokinetics.

[70]  P. du Souich,et al.  First-pass metabolism of lidocaine in the anesthetized rabbit. Contribution of the small intestine. , 1996, Drug Metabolism And Disposition.

[71]  J. Voigt,et al.  Localization, distribution, and induction of xenobiotic-metabolizing enzymes and aryl hydrocarbon hydroxylase activity within lung. , 1990, Pharmacology & therapeutics.

[72]  D. Greenblatt,et al.  Midazolam Hydroxylation by Human Liver Microsomes In Vitro: Inhibition by Fluoxetine, Norfluoxetine, and by Azole Antifungal Agents , 1996, Journal of clinical pharmacology.

[73]  Shand Dg.  Pharmacokinetics of propranolol: a review. , 1976 .

[74]  E. Iisalo.  Clinical Pharmacokinetics of Digoxin , 1977, Clinical pharmacokinetics.

[75]  William H. Press,et al.  The Art of Scientific Computing Second Edition , 1998 .

[76]  Morton B. Brown,et al.  Role of intestinal P‐glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine , 1997, Clinical pharmacology and therapeutics.

[77]  T Ishizaki,et al.  Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. , 1997, Pharmacology & therapeutics.

[78]  K. Pang,et al.  A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[79]  N. Baber,et al.  Bioavailability of sustained release propranolol formulations. , 1981, Biopharmaceutics & drug disposition.